Nkarta(NKTX) - 2024 Q4 - Annual Results

Exhibit 99.1 SOUTH SAN FRANCISCO, Calif., March 26, 2025 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024. Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights "As the validation of cellular therapy in autoimmune disease expands to include CAR NK cells, we remain confident that the potential safety ...